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Abstract
Background: GRADE was developed to address shortcomings of tools to rate the quality of a body of evidence. While much
has been published about GRADE, there are few empirical and systematic evaluations.
Objective: To assess GRADE for systematic reviews (SRs) in terms of inter-rater agreement and identify areas of uncertainty.
Design: Cross-sectional, descriptive study.
Methods: We applied GRADE to three SRs (n=48, 66, and 75 studies, respectively) with 29 comparisons and 12 outcomes
overall. Two reviewers graded evidence independently for outcomes deemed clinically important a priori. Inter-rater
reliability was assessed using kappas for four main domains (risk of bias, consistency, directness, and precision) and overall
quality of evidence.
Results: For the first review, reliability was: k=0.41 for risk of bias; 0.84 consistency; 0.18 precision; and 0.44 overall quality.
Kappa could not be calculated for directness as one rater assessed all items as direct; assessors agreed in 41% of cases. For
the second review reliability was: 0.37 consistency and 0.19 precision. Kappa could not be assessed for other items;
assessors agreed in 33% of cases for risk of bias; 100% directness; and 58% overall quality. For the third review, reliability
was: 0.06 risk of bias; 0.79 consistency; 0.21 precision; and 0.18 overall quality. Assessors agreed in 100% of cases for
directness. Precision created the most uncertainty due to difficulties in identifying ‘‘optimal’’ information size and ‘‘clinical
decision threshold’’, as well as making assessments when there was no meta-analysis. The risk of bias domain created
uncertainty, particularly for nonrandomized studies.
Conclusions: As researchers with varied levels of training and experience use GRADE, there is risk for variability in
interpretation and application. This study shows variable agreement across the GRADE domains, reflecting areas where
further guidance is required.
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Introduction
The GRADE tool (Grading of Recommendations Assessment,
Development and Evaluation) has been developed and refined
over recent years by an international working group (www.
gradeworkinggroup.org). One of the motivations for developing
the tool was to address shortcomings of other approaches to rating
the strength or quality of a body of evidence. The GRADE tool
offers a ‘‘common, sensible, and transparent approach to grading
quality of evidence and strength of recommendations’’. It
represents an important tool for decision-makers as it provides a
mechanism to bridge the gap from evidence synthesis to
application of the evidence for informed decision-making.
Much has been published about the GRADE tool (www.
gradeworkinggroup.org/publications/index.htm). One of the first
citations regarding the GRADE tool appeared in the Canadian
Medical Association Journal in 2003 [1] with a second in the British
Medical Journal soon after [2]. Recently, a series of publications
about the GRADE tool was published in the Journal of Clinical
Epidemiology [3–12]. These reports provide details about the
development of the tool and general instructions on how the tool
should be applied. GRADEPro software is available which offers a
structured format to present the information, with an accompa-
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ims.cochrane.org/revman/gradepro) [13].
In brief, reviewers assess the body of evidence available for a
given question and outcome with respect to several key domains.
These include risk of bias, consistency, precision, directness, and
publication bias. Additional domains that can be considered are
magnitude of effect, confounding, and dose-response relationship.
In general, evidence from randomized trials may start at high
quality while evidence from observational studies starts at low
quality. The evidence can be upgraded or downgraded based on
the remaining domains. This results in a final assessment of quality
of the evidence into one of four categories: high, moderate, low, or
very low. These categories reflect the confidence the assessors have
that the evidence represents the true effect and is unlikely to
change with future research. Assessors are encouraged to
document the reasons for their decisions for transparency.
Use of the GRADE tool has recently been adopted by The
Cochrane Collaboration, and grading the evidence is now a
recommended step within Cochrane systematic reviews [14].
Summary of Findings tables can be developed using GRADEPro
software and integrated into Cochrane reviews. These tables show
effect estimates for key outcomes as well as assessments of the
quality of evidence based on the GRADE tool. This provides an
effective summary of the evidence for the reader. By providing a
quality of evidence assessment alongside the effect estimates, the
reader has some indication of how much confidence they can
place in the findings. Moreover, the reader has a sense of whether
‘‘the evidence reflects the true effect’’ and whether additional
research would likely change the effect estimate or the reader’s
confidence in the estimate [15].
Despite numerous publications about the GRADE tool
(including some criticisms [16]), there have been few empirical
and systematic evaluations of applying the tool in practice [17]. As
grading the evidence is now a recommended step in Cochrane
systematic reviews and in other evidence synthesis initiatives
outside The Cochrane Collaboration [15,18], new users with
variable levels of training are likely to be applying the tool. The
widespread use of the tool by users with variable training has
implications for interpretation and application of the tool.
The objectives of this study were to apply GRADE in systematic
reviews in order to assess inter-rater reliability and identify areas of
uncertainty. Our focus was on use of the tool to rate quality of
evidence, not the strength of recommendations. The goal was to
identify areas that require further guidance in order to provide
clarity for users, particularly systematic reviewers.
Methods
We applied the GRADE tool to three systematic reviews that we
conducted at our research centre [19–21]. The systematic reviews
were broad in scope and each included several interventions and
comparisons. They were on varied clinical topics and involved
different types of interventions (e.g., pharmacological and non-
pharmacological) and outcomes. Further, one included only
randomized controlled trials (RCTs) while the other two also
included select nonrandomized study (NRS) designs. The topics of
the systematic reviews were: 1) steroids and bronchodilators for
bronchiolitis; 2) operative and nonoperative interventions for
rotator cuff tears; and, 3) pain management interventions for hip
fracture (Table 1).
For each review, two reviewers independently graded the
evidence for key outcomes. The outcomes were selected a priori by
the team of investigators associated with each review based on
clinical importance. In general the team of investigators for each
review included at least two clinicians with expertise in the area
and at least one methodologist with expertise in research methods
and systematic reviews. Assessments were made for the four main
domains (risk of bias, consistency, directness, and precision), as
well as overall quality of evidence (high, moderate, low, very low
[or insufficient]) (Table 2). The GRADE tool includes a fifth main
domain (publication bias); however, we followed guidance set out
by the Agency for Healthcare Research and Quality Evidence-
based Practice Center Program which considers publication bias
an optional domain [15]. Further, the GRADE tool has additional
domains, including dose-response association, possible confound-
ing, and strength of association (magnitude of effect); we chose to
focus on the main domains for this study.
Four individuals were involved in assessing the quality of
evidence. All individuals had substantial experience and/or
training in systematic review methods. LH has doctoral level
training in research methods, more than 10 years of SR
experience, and clinical training and experience in rehabilitation
medicine. DD has doctoral level training in epidemiology and
more than 5 years of SR experience. RF is a practicing
pediatrician currently completing a doctoral degree with 4 years
of SR experience. AA-S is a physician with specialty training, a
doctoral degree in research methods, and 6 years of SR
experience. The reviews were assessed by LH and RF (bronchi-
olitis), LH and DD (rotator cuff), and DD and AA-S (hip fracture).
All reviewers read and were familiar with guidance on applying
the GRADE tool [13,15].
Within reviews, we calculated inter-rater reliability between
reviewers for each domain and overall quality of evidence using
kappa statistics. Agreement was categorized as poor (0.00), slight
(0.01–0.20), fair (0.21–0.40), moderate (0.41–0.60), substantial
(0.61–0.80), or almost perfect (0.81–1.00) using one of the standard
approaches [22]. We were unable to calculate kappa if one or both
reviewers in the pair always gave the same assessment for the
domain (e.g., directness always assessed as direct). In this case, we
calculated the percent of assessments within the domain for which
the two reviewers agreed. For each domain, we identified items
that may have led to discrepancies between reviewers. We have
presented this information in a narrative summary.
Results
Overall results are presented in Table 3 and are described by
review and by domain below.
Case 1: Steroids and bronchodilators for bronchiolitis [19]
We included 48 RCTs in this review. We graded the evidence
for six comparisons and four outcomes (Table 1). Further, we
pooled and graded the evidence separately for inpatient and
outpatient populations. There were a total of 51 assessments.
Inter-rater reliability ranged from slight for precision (k=0.18) to
almost perfect for consistency (k=0.84). Reliability for overall
quality of evidence was moderate (k=0.44).
Case 2: Operative and nonoperative interventions for
rotator cuff tears [20]
This review included 27 trials (21 RCTs and 6 controlled
clinical trials) and 39 cohort studies. We graded evidence for 11
comparisons and four outcomes (Table 1). There were a total of 24
assessments. Inter-rater reliability was calculated for two domains
and was slight for precision (k=0.19) and fair for consistency
(k=0.37). Reliability could not be assessed for the other domains
or overall strength of evidence, as one rater assessed all the same.
Applying the GRADE Tool in Systematic Reviews
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Review Comparisons Outcomes
Case 1: Steroids and bronchodilators
for bronchiolitis [19]
N steroid vs. placebo N admissions
N epinephrine vs. placebo N length of stay
N salbutamol vs. placebo N clinical score
N epinephrine vs. salbutamol N adverse events
N epinephrine and dexamethasone
combined vs. placebo
N epinephrine and dexamethasone
combined vs. salbutamol
Case 2: Operative and nonoperative
interventions for rotator cuff tears [20]
N early vs. late surgical RCR N health-related quality of life
N open vs. mini-open RCR N function
N mini-open vs. arthroscopic RCR N time to return to work
N open RCR vs. arthroscopic RCR N cuff integrity
N open or mini-open RCR vs. arthroscopic RCR
N open RCR vs. open or arthroscopic debridement
N
N
N arthroscopic RCR vs. RCR plus acromioplasty
N arthroscopic RCR vs. acromioplasty alone
N single-row vs. double-row suture anchor repairs
N mattress vs. simple stitch
N continuous passive motion with physical
therapy vs. physical therapy alone
Case 3: Pain management interventions
for hip fracture [21]
N analgesia vs. other N acute pain
N spinal vs. general anesthesia N chronic pain
N continuous vs. single administration of
spinal anesthesia
N mortality
N addition of fentanyl to spinal anesthesia N incidence of serious adverse events
N addition of morphine to spinal anesthesia
N addition of sulfentanil to spinal anesthesia
N comparative alternative medicine
N nerve blocks vs. no block
N nerve blocks vs. regional anesthesia
N neurostimulation
N rehabilitation
N traction
RCR=rotator cuff repair.
doi:10.1371/journal.pone.0034697.t001
Table 2. GRADE domains and assessment options*.
Risk of bias Consistency Directness Precision Overall Strength of Evidence
N High N Consistent N Direct N Precise N High
N Medium N Inconsistent N Indirect N Imprecise N Moderate
N Low N Unknown or not applicable N Low
N Insufficient (very low)
*Based on Owens et al. [15].
doi:10.1371/journal.pone.0034697.t002
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directness, and 58% for overall quality of evidence.
Case 3: Pain management interventions for hip fracture
[21]
This review included 65 RCTs and 10 cohort studies. We
graded evidence for 12 comparisons and four outcomes (Table 1)
for a total of 36 assessments. Inter-rater reliability ranged from
slight (k=0.06) for risk of bias to substantial (k=0.79) for
consistency. Reliability for overall quality of evidence was slight
(k=0.18). There was 100% agreement between reviewers for
directness.
Sources of disagreement by domain
Risk of bias. One of the key challenges that arose during
assessment of this domain was how to integrate risk of bias or
quality assessments of the individual studies. This was more
straightforward for RCTs than NRS. For instance, if the majority
of evidence came from RCTs assessed as low risk of bias based on
the Cochrane Risk of Bias tool [14], then we assessed the overall
body of evidence for the comparison and outcome of interest as
low risk of bias. That is, there was room for a fairly direct
translation from assessments using the Risk of Bias tool to the risk
of bias domain. However, there was more discrepancy when other
quality assessment tools were used, particularly for NRS. For
example, questions arose regarding how to translate a range of
scores for cohort studies on the Newcastle Ottawa Scale [23] (from
0 to 9) into one of three risk of bias classifications. Moreover, the
move away from overall quality scores or summaries towards a
component approach for individual studies [14] was found to be
incongruous with forcing an overall assessment of the risk of bias
for a group of studies.
Another question that arose was whether there should be pre-
specified starting points for different study designs. For instance, it
was questioned whether RCTs should always start out as low risk
of bias overall whereas all NRS start out as high risk of bias overall.
One restriction that we noted within the GRADE recommenda-
tions is that NRS are considered as a homogeneous body and start
at high risk of bias. Moreover, they are all referred to as
‘‘observational studies.’’ This does not distinguish between studies
that may be more or less prone to bias based on design features,
such as prospective comparative studies versus a single sample
before-after study. We questioned whether there should be a
distinction among ‘‘observational studies’’ where some would start
at high risk of bias because of key design limitations whereas others
would start at moderate risk of bias based on more rigorous
methodological approaches. For example, in the review of
operative and nonoperative interventions for rotator cuff injuries,
we considered prospective cohort studies that controlled for
confounding to be less prone to bias and graded these higher than
retrospective studies that failed to control for key confounders.
A final key question that arose for the risk of bias domain was
whether there should be different thresholds for different study
designs. For instance, should RCTs always be higher in terms of
risk of bias compared with NRS. Further, should the minimum
threshold for RCTs be moderate risk of bias because the use of an
appropriate randomized design always ensures less risk of bias
compared with NRS. Alternatively, is it ever appropriate to rate
NRS as low risk of bias given that they do not employ
randomization and are always prone to bias due to potential
imbalance between groups being compared, even when rigorous
design or analytic methods are used to attempt to control for
confounding.
Consistency. When a meta-analysis was available for the
comparison of interest, we relied heavily on the I
2 statistic, which
provides an indication of the extent of statistical heterogeneity
across a set of studies [14]. As a general guideline if I
2 was greater
than 50%, the results were considered inconsistent. Similarly if I
2
was less than 20%, the results were considered consistent.
However, these were general guides and were not consistently
applied; there were also areas where judgment was required. More
disagreement arose when there was no meta-analysis. In general,
the reviewers took a qualitative approach to assessing consistency
across studies. For example, they considered whether the estimates
were similar in terms of magnitude and direction of effect, as well
as statistical significance. The somewhat different approach with
and without meta-analysis raises the issue of whether assessments
are made with differential standards depending on whether a
meta-analysis is done. Often the reason for not conducting a meta-
analysis, or pooling data, is due to heterogeneity across studies;
hence, one option is that the default is ‘‘inconsistent’’ or
‘‘unknown’’ when there is no meta-analysis.
Directness. The two main criteria we used to assess this
domain were whether the outcomes were intermediate or
surrogate rather than the final health outcome, and whether the
evidence came from direct head-to-head comparisons. We found
that determining whether an outcome was intermediate or
surrogate was somewhat context-specific and dependent on the
research question posed in the review. For example, pain may be
considered a surrogate or an intermediate outcome related to
function. In the hip fracture review, pain itself was a primary
outcome of interest, whereas in the rotator cuff review, pain was
intermediate and function was among the primary outcomes of
interest. We felt that directness with respect to whether the
outcome is intermediate or surrogate could be determined at the
Table 3. Inter-rater reliability and agreement for GRADE domains and overall strength of evidence.
Domain Case 1 [19] Case 2 [20] Case 3 [21]
Kappa or percent
agreement
Level of agreement
based on kappa
Kappa or percent
agreement
Level of agreement
based on kappa
Kappa or percent
agreement
Level of agreement
based on kappa
Risk of bias 0.41 Moderate 33% n/a 0.06 Slight
Consistency 0.84 Almost perfect 0.37 Fair 0.79 Substantial
Directness 41% n/a 100% n/a 100% n/a
Precision 0.18 Slight 0.19 Slight 0.21 Fair
Overall strength of
evidence
0.44 Moderate 58% n/a 0.18 Slight
doi:10.1371/journal.pone.0034697.t003
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grading the evidence.
We did not assess for applicability within this domain as there
are discrepancies in current published guidance for grading
evidence. One approach restricts the assessment to the two main
criteria above [15], whereas the other approach includes
considerations of generalizability or applicability of the findings
[13]. The first approach considers generalizability outside the
context of grading the evidence and within the context of making
recommendations for application of the evidence, whereas the
second would consider an indirect population as a possible source
of indirectness.
Precision. This domain consistently had low reliability.
Assessments were particularly problematic when no meta-
analysis had been conducted as there was no confidence interval
around a single estimate to determine the inclusion or exclusion of
no effect or important benefit/harm. Similarly, assessment of
precision was difficult when multiple meta-analyses were available
for a given outcome due to differences in how an outcome was
measured across studies. For instance, precision may have varied
between a meta-analysis of pain measured on a continuous scale
and a meta-analysis reporting the proportion of patients
experiencing pain. In these cases, we relied heavily on the
minimum thresholds for number of events (dichotomous
outcomes) or subjects (continuous outcomes) that are specified in
the GRADEPro Handbook [13].
We found it critical to set, a priori, a clinical decision threshold
[12] for each outcome. This is not currently a standard step within
systematic reviews. Furthermore, in some clinical areas there is not
a well-defined or generally accepted threshold; in other cases these
are based on expert opinion or consensus statements and have not
been validated in patient-oriented outcomes. There is a need to
develop this information for different clinical areas and guidance is
needed for how this should be done.
Much of the guidance in the GRADEPro Handbook is directed
toward assessing precision around evidence of effect [13]. There
was, however, a lack of clarity around whether the same rules
apply regarding evidence of no effect. Figure 1 illustrates a finding
of no difference between treatment and placebo with a narrow
confidence interval that does not include an important difference.
Further, the total sample size exceeded the stipulated threshold of
400. However, we were unclear whether the same thresholds
applied in order to rate the finding as precise or whether different
sample size thresholds were needed akin to differences in sample
sizes for trials with different hypotheses (e.g., superiority,
inferiority, non-inferiority, equivalence).
Overall quality of evidence. We found inconsistencies in
our approach to upgrading and downgrading as well as the extent
of upgrading and downgrading. For the most part, we used study
design as our starting point and downgraded by one step for each
domain that was not met; this approach appears to be consistent
with the GRADE recommendation [13]. There were
discrepancies between reviewers in the bottom threshold of
overall quality: some reviewers felt that if there was some
evidence (even from one study), the overall quality should be
rated ‘‘low’’, while ‘‘very low’’ (alternatively referred to as
‘‘insufficient’’ [15]) should be reserved for cases where there was
no evidence at all.
Other general observations
As we gained experience with applying GRADE for various
review topics which had different questions and different types of
evidence, we questioned whether we should aim for consistency
across different bodies of evidence. For instance, should the
evidence for the rotator cuff project, which was generally based on
weak study designs with high risk of bias, ever be rated the same or
higher than topics where the evidence comes only from RCTs. For
instance, in the bronchiolitis review, some of the evidence was
graded as low because it was based on a single trial, therefore the
consistency was unknown and the confidence interval just crossed
the null. However, the trial was at low risk of bias and was
adequately powered to detect differences in the outcome of
interest. Moreover, it was the largest trial conducted to date in the
field, in some cases exceeding the sample size of all the other trials
combined. Yet, the grade of evidence was comparable or in some
cases lower than the body of evidence for the rotator cuff review
which was driven by NRS.
Two additional points were raised during the course of our
work. First, we questioned whether we should develop strict rules
for application of the GRADE tool in the work at our centre with
the intent of increasing agreement between reviewers and across
reviews; or, alternatively provide general guidance and reach
consensus within the different reviews or clinical/topic areas. The
latter approach may yield more inconsistency across reviews
although this may provide important information for the end-user.
For instance, if the reviewers report their agreement, the reader
can judge the extent to which the specific issue is open to judgment
and interpret the evidence more or less cautiously based on this
information.
The second additional point was challenges with terminology.
We found it confusing for the risk of bias domain to use the same
terminology as the process of assessing risk of bias of individual
Figure 1. Example of meta-graph showing no difference in length of stay between treatments.
doi:10.1371/journal.pone.0034697.g001
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confused with quality of studies. Moreover, guidance documents
differentially referred to the same overall assessment as quality of
evidence [13] and strength of evidence [15].
Discussion
Rating a body of evidence using the GRADE tool is becoming
an important and recommended step in systematic reviews and
other evidence synthesis initiatives. Rating the quality of a body of
evidence is valuable for the end-users of evidence syntheses as it
provides an indication of the confidence they can place in the
results. Moreover, it is a key step in translating the body of
evidence into clinical practice guidelines. We undertook this study
to identify areas of uncertainty in applying the GRADE tool in
order to inform the evidence synthesis efforts at our centre. Our
research identified key areas where further guidance is needed to
inform the application of the tool. Specifically, the domains of
precision and risk of bias created the most inconsistency and
challenges, whereas directness and consistency were more
straightforward (although still had substantial disagreement at
times). Further, we encountered challenges when there were no
meta-analyses upon which to base assessments, when outcomes
were measured in different ways, and when evidence included
nonrandomized studies.
Application of the GRADE tool is complex as evidenced by the
series of 20 articles that are currently being published in the Journal
of Clinical Epidemiology [11]. It is clear that both methodological and
clinical expertise is required when applying the GRADE tool.
Further, we believe the GRADE developers would agree that
specific training in use of the GRADE tool is recommended. Our
concern is that with widespread adoption of the GRADE tool in
Cochrane systematic reviews and non-Cochrane synthesis efforts,
there will be inconsistent application of the tool and context-
specific decision rules that emerge. Moreover, different organiza-
tions or researchers may adapt the GRADE approach for their
specific interests, as has already occurred [15,24]. This has the
potential to yield discordant assessments, which will ultimately
affect those using this information to make decisions and
recommendations for clinical care. To alleviate some of these
concerns, all reviews using tools such as GRADE should have a
minimum of two reviewers independently apply the tool, their
agreement should be reported, and the basis for their decisions
should be transparent.
Strengths and limitations
This is one of the first systematic and empirical evaluations of
applying the GRADE tool in systematic reviews. We recognize
that the tool is not meant to eliminate disagreements nor the need
for judgments [11]. Our intent in measuring agreement was to
identify areas of greatest uncertainty and explore reasons for the
discrepancies. We graded the evidence for three systematic
reviews; while the number of reviews was small, there were
numerous comparisons and outcomes within each review (29
comparisons and 12 outcomes overall). The reviews also
represented a variety of clinical topics and types of evidence.
The reviewers who applied the GRADE tool had not undergone
formal training in the use of the tool; however, the reviewers all
had extensive experience and training in research methods and
specifically systematic reviews. We expect that many individuals
who apply the GRADE tool may also do so without formal
training. Hence, our experience reflects what we are likely to see in
practice. Finally, we did not assess the domain of publication bias.
This is specified as one of the main domains in the GRADEPro
Handbook but not by other guidance documents, and specifically
the guidance offered by the stakeholder group for two of our three
reviews [15]. Nevertheless, in most cases, we did not have
sufficient numbers of studies within outcomes and comparisons to
formally test for publication bias.
Conclusions
As the GRADE developers acknowledge, ‘‘refinements are
inevitable’’ for new and innovative tools such as GRADE [11].
The intent of our research was to describe our experience applying
to GRADE tool and to document the areas that created
uncertainty and where clarity and guidance are needed. We trust
that our results will serve to optimize the utility of GRADE as a
tool for evidence synthesis and practice recommendations.
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